Trial Profile
A Phase 2B, Randomized, Controlled Study of HTX-011 Administered Via Pectoral Nerve Block in Subjects Undergoing Upper Extremity Surgery for Augmentation Mammoplasty
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs Bupivacaine/meloxicam (Primary) ; Bupivacaine
- Indications Pain
- Focus Therapeutic Use
- Sponsors Heron Therapeutics
- 05 Oct 2020 Results of pooled analysis of data pooled from 4 studies assessing the safety and plasma concentrations of various doses of HTX-011 in a variety of surgical sites with differing vascularity, presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
- 21 Jun 2018 Primary endpoint (Mean area under the curve (AUC) of the NRS-R pain intensity scores) has been met, according to the Heron Therapeutics media release.
- 21 Jun 2018 Results presented in the Heron Therapeutics media release.